CervoMed (CRVO) Long-Term Investments (2015 - 2024)

CervoMed (CRVO) posted Long-Term Investments of $5.8 million for Q2 2024, up 2222.5% sequentially from $250000.0 in Q4 2015.

CervoMed (CRVO) Long-Term Investments (2015 - 2024) Analysis & Trends

CervoMed has reported Long-Term Investments for 2 years, with the latest figure at $5.8 million in Q2 2024.

Quarterly Long-Term Investments changed N/A year-over-year to $5.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $5.8 million (changed N/A YoY) and the FY2015 annual result came in at $250000.0, changed N/A from the prior year.
Long-Term Investments improved to $5.8 million in Q2 2024 per CRVO's latest filing, from $250000.0 in the prior quarter.
Over five years, Long-Term Investments peaked at $5.8 million in Q2 2024 and troughed at $5.8 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	CervoMed	26.64 Mn	26.64 Mn	-	-

Download Data